Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
Anna Morena D'AliseGuido LeoniGabriella CotugnoLoredana SianiRosa VitaleValentino RuzzaIrene GarziaLaura AntonucciElisa MicarelliVeronica VenafraSven GogovAlessia CaponeSarah RunswickJuan Martín-LiberalEmiliano CalvoVictor MorenoStefan N SymeonidesElisa ScarselliOliver BechterPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
These findings indicate the ability of NOUS-PEV to amplify and broaden the repertoire of tumor-reactive T cells to empower a diverse, potent, and durable antitumor immune response. Finally, a gene signature indicative of the reduced presence of activated T cells together with very poor expression of the antigen-processing machinery genes has been identified in pretreatment biopsies as a potential biomarker of resistance to the treatment.
Keyphrases
- immune response
- genome wide
- poor prognosis
- genome wide identification
- sars cov
- clinical trial
- study protocol
- copy number
- phase iii
- gene expression
- genome wide analysis
- phase ii
- toll like receptor
- dendritic cells
- transcription factor
- long non coding rna
- binding protein
- combination therapy
- bioinformatics analysis
- replacement therapy